The purpose of this study is to assess the efficacy of Diamel administration in the treatment of Polycystic Ovary Syndrome. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks.

Inclusion Criteria:

• Two of the following criteria:

  • Oligo or Anovulation
  • Polycystic Ovary diagnosed by ultrasound technique
  • Clinical signs of Hyperandrogenism

• Signed informed consent

Exclusion Criteria:

• Personal history of other causes of hyperandrogenism: Hyperprolactinemia, suprarenal tumors, ovary tumors, suprarenal hyperplasia, hypercortisolism.
• Patients under other experimental treatment
• Treatment with ovulation inducers and/or insulin sensitizers within 60 days before treatment
• Treatment with vitamins within 7 days before treatment
• Treatment with dietary supplements within 60 days before treatment
• Non-compensated intercurrent diseases: diabetes mellitus, thyroid disease, hypertension